Real-World, First-Line Osimertinib Treatment in Epidermal Growth Factor Receptor Mutation-Positive (EGFRm) Advanced NSCLC

被引：0
|
作者：
Nieva, J. [1 ]
Griesinger, F. [2 ]
Kim, Y. [3 ]
Cohen, A. [4 ,5 ]
Horvat, P. [6 ]
Lu, S. [7 ]
Taylor, A. [8 ]
Yu, N. [8 ]
Sawyer, W. [8 ]
Shenolikar, R. [8 ]
Shaw, S. [8 ]
机构：
[1] Univ Southern Calif, Norris Canc Ctr, Los Angeles, CA 90007 USA
[2] Pius Hosp Oldenburg, D-26121 Oldenburg, Germany
[3] Kyoto Univ, Grad Sch Med, Kyoto, Japan
[4] Flatiron Hlth Inc, New York, NY 10013 USA
[5] NYU, Sch Med, New York, NY USA
[6] Iqvia, Real World Solut, Emea Data Sci Hub, London, England
[7] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China
[8] Astrazeneca, Cambridge, England
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
osimertinib; non-small cell lung cancer; Real-world evidence;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P76.66
引用
收藏
页码：S616 / S617
页数：2
相关论文
共 50 条
  • [31] ELIOS: A multicentre, molecular profiling study of patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib
    Piotrowska, Z.
    Ahn, M-J.
    Pang, Y. K.
    How, S. H.
    Kim, S-W.
    Voon, P. J.
    Cortinovis, D. L.
    De Castro Carpeno, J.
    Tiseo, M.
    Rodriguez Abreu, D.
    Ramalingam, S. S.
    Li, J.
    Servidio, L.
    Sadow, S.
    Hartmaier, R. J.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1420 - S1421
  • [32] Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP)
    Sakata, Yoshihiko
    Saito, Go
    Sakata, Shinya
    Oya, Yuko
    Tamiya, Motohiro
    Suzuki, Hidekazu
    Shibaki, Ryota
    Okada, Asuka
    Yokoyama, Toshihide
    Matsumoto, Hirotaka
    Otsuki, Taiichiro
    Sato, Yuki
    Junji, Uchida
    Tsukita, Yoko
    Inaba, Megumi
    Ikeda, Hideki
    Arai, Daisuke
    Maruyama, Hirotaka
    Hara, Satoshi
    Tsumura, Shinsuke
    Morinaga, Jun
    Sakagami, Takuro
    LUNG CANCER, 2023, 186
  • [33] First-line and beyond: West Midlands real-world data for EGFR mutant (EGFRm) NSCLC
    Powell, R.
    Kussaibati, R.
    Khan, A.
    Sivapalasuntharam, A.
    Wilson, P.
    Chowdhary, R.
    Murukesh, N.
    Jain, A.
    Iqbal, M.
    Ghafoor, Q.
    Baijal, S.
    LUNG CANCER, 2020, 139 : S60 - S61
  • [34] ELIOS: A multicentre, molecular profiling study of patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib
    Piotrowska, Z.
    Ahn, M-J.
    Pang, Y-K.
    How, S. H.
    Sang-We, K.
    Voon, P. J.
    Cortinovis, D. L.
    Carpeno, J. De Castro
    Tiseo, M.
    Abreu, D. Rodriguez
    Ramalingam, S. S.
    Li, J.
    Servidio, L.
    Sadow, S.
    Hartmaier, R. J.
    Cho, B. C.
    ANNALS OF ONCOLOGY, 2022, 33 : S1581 - S1582
  • [35] First-line systemic real-world treatment of patients with advanced/metastatic NSCLC in the UK
    Wang, M.
    Dhokia, P.
    Menon, S.
    Martindale, B.
    ANNALS OF ONCOLOGY, 2018, 29 : 22 - 22
  • [36] FIRST-LINE GEFITINIB IN EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION-POSITIVE (EGFR plus ) NON-SMALL CELL LUNG CANCER (NSCLC) IN AN ISRAELI COHORT
    Ben-Arieh, S.
    Urban, D.
    Maimon, N.
    Leibowitz-Amit, R.
    Keizman, D.
    Biran, H.
    Mishaeli, M.
    Onn, A.
    Gottfried, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 29 - 29
  • [37] Long-term survival and treatment (tx) patterns after first-line (1L) osimertinib in patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive (m) advanced non-small cell lung cancer (NSCLC): Japanese cohort of a global real-world (rw) observational study
    Fujimoto, D.
    Takiguchi, Y.
    Matsumoto, S.
    Yamamoto, N.
    Saito, G.
    Nishimura, Y.
    Sugiyama, S.
    Oku, A.
    Karia, P.
    Antunes, L.
    Chapaneri, J.
    Salomonsen, R. J-B.
    Martin, E.
    Okhuoya, P.
    Muto, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S1657 - S1658
  • [38] Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts
    Ramalingam, S.
    Yang, J. C. -H.
    Lee, C. K.
    Kurata, T.
    Kim, D. -W.
    John, T.
    Nogami, N.
    Ohe, Y.
    Janne, P. A.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S152 - S152
  • [39] Tumour genomics in patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib in the phase II ELIOS study
    Ahn, M-J.
    Cho, B. C.
    Pang, Y. K.
    Voon, P. J.
    Kim, S-W.
    De Castro Carpeno, J.
    Tiseo, M.
    Li, J.
    Servidio, L.
    Sadow, S.
    Markovets, A.
    Tang, K. H.
    Piotrowska, Z.
    ANNALS OF ONCOLOGY, 2022, 33 : S1563 - S1564
  • [40] Utility of longitudinal circulating tumor DNA (ctDNA) modeling to predict RECIST-defined progression in first-line patients with epidermal growth factor receptor mutation-positive (EGFRm) advanced non-small cell lung cancer (NSCLC)
    Vishwanathan, Karthick
    Dunyak, James
    Overend, Philip
    Hartmaier, Ryan
    Markovets, Aleksandra
    Chmielecki, Juliann
    Mugundu, Ganesh
    Barrett, Carl
    Tomkinson, Helen
    Johnson, Martin
    CANCER RESEARCH, 2020, 80 (16)
12345